论文部分内容阅读
目的检测非小细胞肺癌患者化疗前外周血血管内皮生长因子的水平,探讨其与化疗疗效、预后的关系。方法酶联免疫吸附试验检测78例NSCLC患者化疗前血清VEGF水平,并采用x2检验、Kaplan-Meier生存曲线比较与VEGF表达相关因素及其对生存期的影响。结果在NSCLC中,血清VEGF阳性率为30.8%(24/78)。VEGF的表达与淋巴结转移、远处转移、TNM分期、化疗疗效密切相关,但与年龄、性别、病理类型等无关。VEGF阳性组的生存期与阴性组相比接近统计学意义(P=0.0741)。结论检测NSCLC患者外周血VEGF,可能有利于协助预测转移、评价化疗疗效及判断预后。
Objective To detect the level of peripheral blood vascular endothelial growth factor (VEGF) before chemotherapy in patients with non-small cell lung cancer (NSCLC) and to explore its relationship with the curative effect and prognosis of chemotherapy. Methods The serum levels of VEGF in 78 patients with NSCLC before chemotherapy were detected by enzyme-linked immunosorbent assay (ELISA). The correlations between VEGF expression and survival were analyzed by x2 test and Kaplan-Meier survival curve. Results In NSCLC, the positive rate of serum VEGF was 30.8% (24/78). The expression of VEGF is closely related to lymph node metastasis, distant metastasis, TNM staging and chemotherapy efficacy, but not with age, gender, pathological type and so on. The survival of the VEGF-positive group was similar to that of the negative group (P = 0.0741). Conclusion Detecting peripheral blood VEGF in patients with NSCLC may be helpful to predict the metastasis, evaluate the curative effect of chemotherapy and prognosis.